Počet záznamů: 1

Genetically modified cellular vaccines against human papillomavirus type 16 (HPV16)-associated tumors: adjuvant treatment of minimal residual disease after surgery/chemotherapy

  1. 1.
    0346751 - UMG-J 2011 RIV GR eng J - Článek v odborném periodiku
    Bubeník, Jan - Šímová, Jana
    Genetically modified cellular vaccines against human papillomavirus type 16 (HPV16)-associated tumors: adjuvant treatment of minimal residual disease after surgery/chemotherapy.
    Journal of Balkan Union of Oncology. Roč. 14, č. 1 (2009), s. 169-173 ISSN 1107-0625
    Grant CEP: GA ČR GA301/06/0774; GA ČR GA301/07/1410
    GRANT EU: European Commission(XE) 18933 - CLINIGENE
    Výzkumný záměr: CEZ:AV0Z50520514
    Klíčová slova: residual tumour disease * HPV16 * cellular vaccines
    Kód oboru RIV: EB - Genetika a molekulární biologie
    Impakt faktor: 0.600, rok: 2009

    Local recurrences at the site of tumour resection or after chemotherapy, as well as distant micrometastases represent major problems in oncology. Genetically modified cellular vaccines were found to be efficient against cancer both in experimental models and in tumour-bearing patients. It was also shown in various systems that the efficacy of conventional therapeutic modalities can be supported by adjuvant administration of genetically modified vaccines, as well as by depletion of immunosuppressive immunocyte subsets. The purpose of this review is to summarize and evaluate the results obtained with administration of genetically modified cellular vaccines as well as with depletion of immunosuppressive immunocytes performed as treatment of the minimal residual tumour disease after surgery / chemotherapy in the experimental model of murine tumours mimicking human HPV 16-associated neoplasms. The prospects and limitations of these adjuvant immunotherapeutic modalities will be discussed.
    Trvalý link: http://hdl.handle.net/11104/0187687